These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28366995)

  • 1. Effects of rikkunshito on quality of life in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy.
    Kawai T; Hirayama Y; Oguchi A; Ishii F; Matushita M; Kitayama N; Morishita S; Hiratsuka N; Ohata K; Konishi H; Kishino M; Nakamura S
    J Clin Biochem Nutr; 2017 Mar; 60(2):143-145. PubMed ID: 28366995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rikkunshito improves globus sensation in patients with proton-pump inhibitor-refractory laryngopharyngeal reflux.
    Tokashiki R; Okamoto I; Funato N; Suzuki M
    World J Gastroenterol; 2013 Aug; 19(31):5118-24. PubMed ID: 23964146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
    Shirai Y; Kawami N; Iwakiri K; Kuwana M
    J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
    Kindt S; Imschoot J; Tack J
    Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent reflux symptoms cause anxiety, depression, and mental health and sleep disorders in gastroesophageal reflux disease patients.
    Kimura Y; Kamiya T; Senoo K; Tsuchida K; Hirano A; Kojima H; Yamashita H; Yamakawa Y; Nishigaki N; Ozeki T; Endo M; Nakanishi K; Sando M; Inagaki Y; Shikano M; Mizoshita T; Kubota E; Tanida S; Kataoka H; Katsumi K; Joh T
    J Clin Biochem Nutr; 2016 Jul; 59(1):71-7. PubMed ID: 27499583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.
    Richter JE
    Gastroenterol Hepatol (N Y); 2014 Sep; 10(9):547-55. PubMed ID: 27551249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of proton pump inhibitor in combination with rikkunshito in patients complaining of globus pharyngeus.
    Nakano S; Iwasaki H; Kondo E; Miyazaki K; Shizuku H; Kamimura S; Fukuda J; Kanamura R; Takeda N
    J Med Invest; 2016; 63(3-4):227-9. PubMed ID: 27644563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
    Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
    Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory Heartburn: A Challenging Problem in Clinical Practice.
    Domingues G; Moraes-Filho JPP; Fass R
    Dig Dis Sci; 2018 Mar; 63(3):577-582. PubMed ID: 29352757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of rikkunshito, a Japanese kampo medicine, on gastrointestinal dysfunction and anorexia in combination with Western drug: a systematic review.
    Mogami S; Hattori T
    Evid Based Complement Alternat Med; 2014; 2014():519035. PubMed ID: 24778703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between symptomatic improvement and quality of life in patients with reflux and dyspeptic symptoms.
    Arihiro S; Kato T; Ito K; Saruta M; Nikami T; Suzuki T; Tajiri H
    J Clin Biochem Nutr; 2012 May; 50(3):205-10. PubMed ID: 22573922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal Motility and Rikkunshito Treatment for Proton Pump Inhibitor-Refractory Nonerosive Reflux Disease: A Prospective, Uncontrolled, Open-Label Pilot Study Trial.
    Odaka T; Yamato S; Yokosuka O
    Curr Ther Res Clin Exp; 2017; 84():37-41. PubMed ID: 28761578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.
    Armstrong D; Veldhuyzen SJ; Chung SA; Shapiro CM; Dhillon S; Escobedo S; Chakraborty BK; Mann V; Tanser L; Nevin K
    Can J Gastroenterol; 2005 Jun; 19(6):350-8. PubMed ID: 15997268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
    Dickman R; Schiff E; Holland A; Wright C; Sarela SR; Han B; Fass R
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1333-44. PubMed ID: 17875198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.